HEALTH TECHNOLOGY

WELL Forms Canadian Clinics Business Unit, Expands Credit Agreement, and Ramps up Clinic Growth

WELL Health Technologies Corp. | July 15, 2022 | Read time : 3 min

WELL Forms

WELL Health Technologies Corp. a practitioner focussed digital health company positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce it has formed a new legal entity called WELL Health Canada Clinics Inc. to house its Canadian omni-channel clinical businesses. These businesses include the Company's previous Primary Care, Allied Care and MyHealth Specialized Care business units.

The Canadian Clinics Business Unit represents WELL's owned and operated fleet of Omni-Channel outpatient clinics leveraging WELL's highly integrated 'hybrid' brick and mortar and virtual service capabilities and includes the Company's primary care, specialized care, allied health, and diagnostics services but does not include the Company's TiaHealth.com service which is part of WELL's Virtual Services division. This business unit supports almost 1,300 healthcare practitioners who provide 1.87 million patient visits annually on a run-rate basis(2);  over 40% of these patients are seen remotely via one of WELL's virtual or telehealth platforms, with the remainder treated in one of WELL's 81 Canadian clinics(3).  This business is also expected to generate revenues exceeding $160 million with double digit operating Adjusted EBITDA(4) margins. Driven by WELL's consolidation and capital allocation efforts, this business has been experiencing organic growth rates approaching double digit percentage growth. The Canadian Clinics business unit is a key pillar in WELL's mission to empower practitioners.

Dr. Michael Frankel, WELL's Chief Medical Officer, said "This consolidation of our Canadian clinics business provides WELL with the proper foundation to become a national health system providing the very best in highly integrated 'bricks and clicks' care.  We are excited to provide healthcare practitioners with a compelling home where they are supported with exceptional front and back-office support and technology solutions so they can provide critical care to their patients.  We intend on further developing our services from coast to coast." 

WELL will look to continue its consolidation and modernization of healthcare resources in Canada powered by its organic growth and with the help of its funding partners RBC, the Bank of Montreal, HSBC Bank Canada, The Toronto-Dominion Bank, ICICI Bank Canada and Laurentian Bank of Canada (collectively the "Lenders").  RBC is the Lead Arranger, Sole Bookrunner, and Administrative Agent on the financing.  The Lenders have amended previous MyHealth credit facilities to include the newly formed Canadian Clinics Business Unit, as well as provided an extension of their credit commitments for an incremental year, extending the maturity to June 2026.  The facilities are currently priced at an interest rate which is equivalent to SOFR/CDOR plus 1.25% to 3.25%(5), depending on the debt to Adjusted EBITDA ratio of the consolidated results for the Canadian Clinics Business Unit.

WELL's goal is to continue to grow Canada's largest network of outpatient clinics using a combination of greenfield sites and new acquisitions.  WELL is pleased to confirm that it has added a primary care clinic in Vancouver to its network and a new greenfield haemorrhoid treatment center in Hamilton, Ontario. The Company's combined investment to add these two clinics to the network is less than $100k. The combined annual revenues of the two clinics are expected to exceed $2 million in their first year under WELL and be profitable. The Company's recently announced acquisition of Calgary based InLiv, a premium provider of healthcare services in the Province of Alberta, will also be part of the Canadian Clinics Business Unit upon closing and is expected to exceed $7 million per year in revenues with 85% of such revenue reflecting recurring membership revenue.

"We are thrilled to have the continued support of our banking partners and to announce the amendments to our existing Canadian credit facilities. Our ability to expand our Canadian credit agreement with favourable terms in the present challenging macroeconomic environment is not only a testament to the fantastic support we are receiving from our banking partners but also the strength of WELL's outpatient clinic business.  The updated credit facilities allow us to more efficiently deploy capital towards our strategic priorities and generate more shareholder value by improving our revenue and Adjusted EBITDA per share metrics."

Hamed Shahbazi, CEO and Founder of WELL

WELL's objective is to continue to grow its Canadian Clinics Business Unit both organically and inorganically and continue to demonstrate market leadership as the country's first pan-Canadian clinical network with a highly integrated network of tech-enabled outpatient healthcare clinics across the country.

About WELL Health Technologies Corp.
WELL is a practitioner focused digital healthcare company whose overarching objective is to positively impact health outcomes to empower and support healthcare practitioners and their patients. WELL has built an innovative practitioner enablement platform that includes comprehensive end to end practice management tools inclusive of virtual care and digital patient engagement capabilities as well as Electronic Medical Records (EMR), Revenue Cycle Management (RCM) and data protection services. WELL uses this platform to power healthcare practitioners both inside and outside of WELL's own omni-channel patient services offerings. As such, WELL owns and operates Canada's largest network of outpatient medical clinics serving primary and specialized healthcare services and is the provider of a leading multi-national, multi-disciplinary telehealth offering. WELL is publicly traded on the Toronto Stock Exchange under the symbol "WELL" and on OTCQX under the symbol "WHTCF". 

Spotlight

Vivian, software engineer, with our medical device teams collaborates for success.

Spotlight

Vivian, software engineer, with our medical device teams collaborates for success.

Related News

DIGITAL HEALTHCARE, HEALTHCARE ANALYTICS

Long-Duration Ultrasound Treatment With sam® Elevates Regenerative Medicine Options for Patients

ZetrOZ Systems | December 13, 2022

Sustained Acoustic Medicine technology, the FDA-cleared ultrasound device created by ZetrOZ Systems, continues to demonstrate its ability to relieve pain and accelerate patients' return to sports, work and other daily activities. Now, medical professionals can administer the innovative technology as a pre- and post-treatment recovery option for regenerative medicine injectable treatments such as platelet-rich plasma and other autologous cellular-based therapies. PRP injections are safe, autologous blood products containing growth factors and cytokines with the potential to alter biological processes and support the three phases of tissue healing: inflammation, proliferation, and remodeling. PRP injections are commonly administered in the doctor's office multiple times over six to 12 months and may be painful to some patients. sam® offers a non-invasive, daily, home-use treatment option for pain and tissue remodeling, which is a powerful technology to complement PRP injections and other regenerative medicine therapies. "Sustained acoustic medicine is a powerful mechanobiological treatment modality," said Dr. George Lewis, founder and CEO of ZetrOZ Systems. "Each treatment increases vessel diameter to boost blood flow over several hours, accelerating tissue healing and delivering a significant reduction in pain for patients. The use of ultrasound and shockwave treatment in the clinical setting to complement rehabilitation and regenerative medicine is broadly used. sam® is the first long-duration ultrasound treatment available for prescription home use." The use of sam® is also continuing to expand in the professional sports medicine market, with ongoing use by 75% of professional and college affiliations, including the NFL, NBA, MLS, WBNA, MLB and the ACC. ZetrOZ Systems also partners with all professional sports organizations and sports medicine providers in Atlanta, GA, and are proud supporters of the healthcare and athletic training societies of the NFL, MLB, NHL, NBA and MLS. sam® treats over 35% of muscle and tendon injuries without surgery, helping elite athletes and professionals in physically demanding jobs get pain relief and natural healing. "Surgery is not always the best course of action for our athletes, and sam® technology offers a pathway to recovery without invasive surgery that can have risks and implications immediately or in the future," Lewis said. Ultrasound therapy continues to show promise, with more than 40 peer-reviewed studies showing that sam® offers faster healing after injury or surgery. These findings can empower care providers to offer this easy-to-use regenerative device that leads to better outcomes, happier patients, and lowers healthcare system costs. The technology can serve as a standalone treatment or adjunct to other treatment options for patients to stimulate soft-tissue repair. About ZetrOZ Systems ZetrOZ Systems is leading healing innovation in sports medicine, developing wearable bioelectronic devices for the delivery of sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on proprietary medical technology of +46 patents. The exclusive manufacturer and developer of the sam® product line is designed for the treatment of acute and chronic musculoskeletal conditions.

Read More

DIGITAL HEALTHCARE, MEDICAL DEVICES

Virgin Pulse and Medsphere Enter into a Collaborative Agreement to Support Health Systems’ Growth

Medsphere Systems Corporation | December 15, 2022

Virgin Pulse, the leading global digital-first health, wellbeing, and navigation company, announced that it has entered into a collaborative agreement with Medsphere Systems Corporation, the leading provider of affordable and interoperable healthcare IT platform solutions and services. The two companies have established a long-term referral partnership that makes Medsphere’s Marketware physician relationship management (PRM) platform the preferred solution for Virgin Pulse clients; Virgin Pulse is now the preferred customer relationship management, patient acquisition and retention, and data/analytics solution provider for Marketware clients. “Our Homebase for Health platform and strategy is focused on providing the market with a comprehensive digital health activation and engagement solution that unifies health, wellbeing, and navigation for clients and consumers. As we looked across our solution set, we recognized that our PRM offering was sitting slightly adjacent to that core strategy. To ensure that our health system clients are getting the latest advancements in provider relations, we are helping transition them to Marketware’s PRM. We look forward to introducing Marketware clients to our growing offerings for patient acquisition and retention as well.” Jeff Yoshimura, chief product officer for Virgin Pulse Virgin Pulse will continue to offer and invest in VP Activate, which delivers data-driven, multi-channel outreach capabilities – including CRM/patient acquisition and retention – that drive people to take critical health actions. VP Activate leverages real-time data and engagement experts to accurately identify and reach up to 95% of targets with integrated digital and offline channels that maximize campaign results. The Marketware division of Medsphere is transitioning Virgin Pulse clients who are currently using the Physicianology PRM solution to its best-in-class PRM platform moving forward. Virgin Pulse is discontinuing Physicianology as of December 31, 2022. “Hospitals and health systems today face challenges when it comes to managing both their physician network and patient populations, creating a prime opportunity for technologies from Marketware and Virgin Pulse to make a big difference,” said Josh Cameron, executive vice president, Marketware Division of Medsphere. “We look forward to working with Virgin Pulse to support health systems by maximizing our core competencies to help them reach their goals. We also welcome Virgin Pulse PRM clients to Marketware and are committed to providing them with a high-quality experience.” About Marketware Marketware’s Physician Relationship Management (PRM) platform makes it easier than ever to plan, track and measure the effectiveness of liaison activity across key growth initiatives. With Marketware, healthcare organizations are better armed to prevent physician turnover and loss of revenue by keeping close track of organized timelines and task assignments. Recruiters and C-level decision makers can review the responsiveness of physician recruits and close the loop on any obstacles to access or service issues. About Virgin Pulse Virgin Pulse is the leading digital-first health, wellbeing, and navigation company that empowers organizations across the globe to activate populations, improve health outcomes, and reduce spend in an era of accelerating cost and complexity. Virgin Pulse’s Homebase for Health® connects data, people, and technology to deliver high tech, human touch experiences that engage and reward individual journeys. Virgin Pulse impacts over 100 million people across 190 countries by helping Fortune 500, national health plans, and many other organizations change lives – and businesses – for good.

Read More

HEALTHTECH SECURITY,FUTURE OF HEALTHCARE

Sightpath Medical Acquires Accusite Surgical

Sightpath Medical | November 22, 2022

Sightpath Medical, the leading provider of mobile ophthalmic services for cataract and refractive surgery, announced that it has acquired Accusite Surgical, a cataract surgery equipment outsourcing company. Founded in 1991, Sightpath Medical delivers custom access to advanced ophthalmic equipment, instruments, and services to facilities and surgeons across the United States. Through its patented technology, the company was the first to mobilize phacoemulsification machines, excimer lasers, the IntraLase Femtosecond Laser, and the LenSx Femtosecond Laser. Sightpath Medical has earned the trust of medical professionals and patients nationwide through the quality of its equipment, the skill of its employees, and the dedication and responsiveness of its staff. Accusite Surgical is a mobile cataract surgical company that outsources state-of-the-art equipment, technology, and certified staff to surgeons, ambulatory surgical centers, and hospitals. For over 28 years, the company has assisted in more than 200,000 procedures throughout the Southeastern U.S. In connection with the transaction, D. Lynn Godfrey, Founder and Chief Executive Officer of Accusite Surgical, will join Sightpath Medical as Chief Strategy Officer. “This strategic combination bolsters Sightpath Medical’s market-leading position and enhances our ability to deliver variable, tailored access to the expert personnel, equipment, and supplies surgeons need to provide critical eye care. We are delighted to begin integrating the Accusite Surgical business into ours and are equally excited to welcome Lynn Godfrey, who is an experienced and creative executive, to our management team. We look forward to growing Sightpath Medical together.” Joel Gaslin, President and CEO of Sightpath Medical Mr. Godfrey added, “After 28 years, I began exploring the long-term options for my business and quickly determined that the Sightpath Medical executive team and its financial partner, MGG Investment Group, were the right partners for Accusite Surgical. We are closely aligned on our core mission of helping surgeons and their referring Optometrists provide patients with excellent eye care and, ultimately, better vision. I am thrilled to commence Accusite Surgical’s next chapter as part of Sightpath Medical.” About Sightpath Medical Sightpath Medical is the leading U.S. provider of mobile ophthalmic services for cataract, refractive and laser-assisted surgery. Working alongside more than 1,200 surgeons and the staffs of their surgical facilities for more than 30 years, Sightpath Medical is the market-leading choice for surgeons, ASCs, and hospitals due to our proven ability to deliver the staff, equipment, and supplies wherever and whenever they are needed – regardless of geography. About Accusite Surgical For nearly three decades, Accusite Surgical has been a leading provider of state-of-the-art equipment, supplies, and support for cataract surgery in the Southeastern United States. Accusite Surgical is a trusted partner to ASCs and hospitals and ophthalmologists for cataract surgery services and is committed to helping surgeons grow their practices while delivering superior outcomes for patients.

Read More